Background: Human immunodeficiency virus (HIV) infection itself and highly active antiretroviral treatment (HAART) have been proposed to be associated with a higher prevalence of metabolic syndrome, but, to date, prevalence and phenotype of metabolic syndrome among HIV subjects and the related structural and functional vascular alterations are not conclusively defined. Methods: We analyzed the data of 108 HIV-infected subjects without known cardiovascular risk factors: 72 were on HAART (group A, age 46.57.5 years, clinical blood pressure 125.7/74.911.6/7.8mmHg) and there 36 in a naive group (group B, age 40.7 +/- 7.9 years, blood pressure 126/75.8 +/- 9.8/7.7mmHg). A total of 224 healthy subjects served as controls (group C, age 44.9 +/- 6.9 years, blood pressure 123.7/75.7 +/- 9.8/7.1mmHg). Arterial stiffness was measured by aorto-femoral pulse wave velocity (PWV, sfigmocor), and carotid intima media thickness (IMT) was measured by a semiautomatic echotracking system (Esaote-WTS). Results: Metabolic syndrome was more frequent in HIV-positive subjects than in controls (19.4%, 13.8%, 4.5% for groups A, B, and C; P<0.001), with no significant difference between HAART and naive. In metabolic syndrome subjects, group A displayed lipid profile alterations more frequently (91%, 50%, 57% for groups A, B, and C; P<0.05), whereas others metabolic syndrome components were equally represented in the three groups. In metabolic syndrome subjects, IMT was similar [556 +/- 108, 542 +/- 164, and 564 +/- 110.4 m for groups A, B, and C; P=not significant (NS)], whereas PWV was significantly greater in HAART subjects when compared with controls (10.8 +/- 1.8, 9.+/- 1.1, 9.3 +/- 1cm/sec for groups A, B, and C; P=0.02 for A vs. C). Moreover, in this group (metabolic syndrome+HAART), PWV was higher than in subjects on HAART but without metabolic syndrome. Conclusions: HIV subjects showed a higher prevalence and a different pattern of metabolic syndrome components. HAART, more than HIV infection per se, appeared to be responsible for the increased prevalence of metabolic syndrome and arterial function derangement.

Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function / A. Maloberti, C. Giannattasio, D. Dozio, M. Betelli, P. Villa, S. Nava, F. Cesana, R. Facchetti, L. Giupponi, F. Castagna, F. Sabbatini, A. Bandera, A. Gori, G. Grassi, G. Mancia. - In: METABOLIC SYNDROME AND RELATED DISORDERS. - ISSN 1540-4196. - 11:6(2013), pp. 403-411. [10.1089/met.2013.0008]

Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function

A. Bandera;A. Gori;
2013

Abstract

Background: Human immunodeficiency virus (HIV) infection itself and highly active antiretroviral treatment (HAART) have been proposed to be associated with a higher prevalence of metabolic syndrome, but, to date, prevalence and phenotype of metabolic syndrome among HIV subjects and the related structural and functional vascular alterations are not conclusively defined. Methods: We analyzed the data of 108 HIV-infected subjects without known cardiovascular risk factors: 72 were on HAART (group A, age 46.57.5 years, clinical blood pressure 125.7/74.911.6/7.8mmHg) and there 36 in a naive group (group B, age 40.7 +/- 7.9 years, blood pressure 126/75.8 +/- 9.8/7.7mmHg). A total of 224 healthy subjects served as controls (group C, age 44.9 +/- 6.9 years, blood pressure 123.7/75.7 +/- 9.8/7.1mmHg). Arterial stiffness was measured by aorto-femoral pulse wave velocity (PWV, sfigmocor), and carotid intima media thickness (IMT) was measured by a semiautomatic echotracking system (Esaote-WTS). Results: Metabolic syndrome was more frequent in HIV-positive subjects than in controls (19.4%, 13.8%, 4.5% for groups A, B, and C; P<0.001), with no significant difference between HAART and naive. In metabolic syndrome subjects, group A displayed lipid profile alterations more frequently (91%, 50%, 57% for groups A, B, and C; P<0.05), whereas others metabolic syndrome components were equally represented in the three groups. In metabolic syndrome subjects, IMT was similar [556 +/- 108, 542 +/- 164, and 564 +/- 110.4 m for groups A, B, and C; P=not significant (NS)], whereas PWV was significantly greater in HAART subjects when compared with controls (10.8 +/- 1.8, 9.+/- 1.1, 9.3 +/- 1cm/sec for groups A, B, and C; P=0.02 for A vs. C). Moreover, in this group (metabolic syndrome+HAART), PWV was higher than in subjects on HAART but without metabolic syndrome. Conclusions: HIV subjects showed a higher prevalence and a different pattern of metabolic syndrome components. HAART, more than HIV infection per se, appeared to be responsible for the increased prevalence of metabolic syndrome and arterial function derangement.
HIV-infected patients; active antiretroviral therapy; insulin-resistance; cardiovascular-disease; aortic stiffness; data-collection; adverse events; risk-factors; subclinical atherosclerosis; myocardial-infarction
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/642607
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact